← All Cardiff Oncology, INC filings

Cardiff Oncology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CRDF
Cardiff Oncology, INC
10-K: Cardiff Oncology Faces Going Concern Doubt Amid Clinical Progress
Cardiff Oncology's latest 10-K reveals promising clinical trial data for onvansertib in mCRC and mTNBC, but highlights significant financial challenges and a going concern warning.
NASDAQ
CRDF
Cardiff Oncology, INC
10-K: Cardiff Oncology Reports 2024 Financial Results and Provides Business Update
Cardiff Oncology, a clinical-stage biotechnology company, details its financial performance for 2024 and outlines key developments in its oncology drug development programs.
NASDAQ
CRDF
Cardiff Oncology, INC
10-K: Cardiff Oncology Files 10-K Annual Report, Provides Update on Clinical Programs
Cardiff Oncology's 10-K filing details the company's financial status, clinical trial progress, and future plans, highlighting its focus on onvansertib development.